Can a biologic like Humira, Stelara or Entyvio be compounded?

A biologic is grown, not mixed

Most medicines are small chemicals that a pharmacy can weigh out and blend. A biologic is made by living cells, and most are large proteins, produced in a process the manufacturer controls from start to finish. Antibody medicines are a large group of them: their generic names end in "-mab", as in adalimumab (Humira), ustekinumab (Stelara) and vedolizumab (Entyvio). FDA says of biologics that they "cannot be copied exactly."

Federal law leaves no room for it

Compounding pharmacies work under two sections of federal law, known as 503A and 503B. FDA's guidance says biological products "are not eligible for the exemptions for compounded drugs" under either one, and that the law "does not provide a legal pathway" for selling a biologic prepared outside the manufacturer's license. A prescription, a shortage or a medical reason does not change that.

What pharmacies and infusion centers do instead

They prepare your dose from the manufacturer's product: mixing an infusion bag, or drawing a dose into a syringe. FDA allows that under set conditions. Nobody but the manufacturer makes the medicine itself, which is why no compounding pharmacy can offer you a lower-priced version of it.

1. With insurance from an employer or the marketplace: the manufacturer's savings program

Check this first. Each of the seven brands below runs a co-pay program for people with commercial insurance. When we looked, the Humira and Entyvio programs each advertised a co-pay of "as little as $0" for people who qualify, up to a yearly limit ($14,000 for Humira, $20,000 for Entyvio). You enroll on the manufacturer's site or by phone, and your prescriber's office can often do it with you. One limit applies to all of them: they cannot be used with Medicare, Medicaid, TRICARE or other government coverage.

• Humira: HUMIRA Complete Savings Card
• Skyrizi: Skyrizi Complete Savings Card
• Stelara: STELARA withMe Savings Program
• Remicade: J&J withMe Savings Program for REMICADE
• Dupixent: DUPIXENT MyWay Copay Card
• Enbrel: ENBREL Co-Pay Program
• Entyvio: EntyvioConnect Co-Pay Program

For any other brand, search its name with "savings program" and use the manufacturer's own website.

2. Ask whether a biosimilar is available

A biosimilar is to a biologic roughly what a generic is to an ordinary medicine. FDA requires that it have "no clinically meaningful differences" from the original, says biosimilars "are as safe and effective as the original biologic," and says they "may cost less." On FDA's list dated October 28, 2026, approved biosimilars exist for Humira, Remicade, Enbrel, Stelara, Actemra, Tysabri, Prolia and Xgeva, and Xolair, among others. None is listed yet for Entyvio, Skyrizi, Dupixent or Cosentyx. Being approved does not always mean a biosimilar is being sold yet, and an insurance plan may prefer one in particular, so ask your prescriber and your insurer which they would use.

• FDA: approved biosimilar products
• FDA: what a biosimilar is

3. If it is an infusion, ask where it will be given

The same infusion can be billed very differently depending on the building. A study of 52,760 infusions given in 2022 and 2023 to adults with commercial insurance found outpatient costs 41.9% higher at hospital outpatient departments than at infusion centers, doctors' offices and at home, with no significant difference in side effects. It was done by researchers at the insurer Elevance Health and published in the Journal of Managed Care & Specialty Pharmacy. The study measured the cost of the care, not what patients themselves paid. But if you owe a percentage of the bill, the total is what your share is taken from. Ask your insurer what you would owe at each place in your network, and ask your prescriber whether an infusion center or home infusion suits your treatment.

• Find an infusion center near you (National Infusion Center Association)
• The study (PubMed)

The locator is run by the trade association for infusion centers outside hospitals, and centers keep their own listings.

4. On Medicare

Manufacturer co-pay cards cannot be used with Medicare, so the help comes from Medicare itself. An infusion or injection given by a provider usually falls under Part B: Medicare says you pay up to 20% of the approved amount after the Part B deductible, and a Medigap or Medicare Advantage plan may change that. A medicine you inject yourself is usually covered by your Part D drug plan instead. There, your out-of-pocket spending on covered drugs stops at $2,100 in 2026 ($2,400 in 2027), and you pay nothing more for covered Part D drugs for the rest of the year. Extra Help lowers Part D costs for people with limited income. Independent charities can sometimes pay co-pays that a manufacturer legally cannot; their funds open and close through the year.

• Medicare: drugs covered under Part B
• Medicare: what Part D drug coverage costs
• Medicare: Extra Help with drug costs
• HealthWell Foundation
• TotalAssist (Patient Advocate Foundation)

5. With no insurance, or when it still costs too much

Call the manufacturer's program anyway. Several run a separate patient assistance program for people who are uninsured or cannot afford the medicine: Dupixent MyWay has one, and the Entyvio and Stelara programs both say they help people with no insurance look for assistance. Qualifying usually depends on your income and coverage, and your prescriber's office usually has to complete part of the application.